Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 15/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 10/20 | 0.48 |
| ▸ | CDK9 | P50750 | 10/20 | 0.48 |
| ▸ | CCNH | P51946 | 9/20 | 0.48 |
| ▸ | MNAT1 | P51948 | 8/20 | 0.48 |
| ▸ | CCNK | O75909 | 8/20 | 0.46 |
| ▸ | CDK12 | Q9NYV4 | 8/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.44 |
| ▸ | CDK2 | P24941 | 6/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16665106 | 0.85 | CDK7 (0.46) | CDK7CCNT1CDK9CCNHMNAT1 | |
| SCHEMBL19040097 | 0.81 | CDK7 (0.72) | CDK7CCNT1CDK9CCNHMNAT1 | |
| SCHEMBL20412342 | 0.81 | CDK7 (0.72) | CDK7CCNT1CDK9CCNHMNAT1 | |
| SCHEMBL18069808 | 0.81 | CDK7 (0.44) | CDK7CCNT1CDK9CCNHMNAT1 | |
| Trifluoromethanesulfonic Acid SCHEMBL18047297 | 0.80 | CDK7 (0.42) | CDK7CCNT1CDK9CCNHMNAT1 | |
| SCHEMBL19600360 | 0.79 | CDK7 (0.56) | CDK7CCNT1CDK9CCNHMNAT1 | |
| Hydrochloric Acid SCHEMBL17688367 | 0.78 | CDK7 (0.55) | CDK7CCNT1CDK9CCNHMNAT1 | |
| SCHEMBL17151970 | 0.77 | CDK9 (0.52) | CDK7CCNT1CDK9CCNHMNAT1 | |
| SCHEMBL18069810 | 0.77 | CDK7 (0.53) | CDK7CCNT1CDK9CCNHMNAT1 | |
| SCHEMBL18074083 | 0.76 | CDK7 (0.42) | CDK7CCNT1CDK9CCNHMNAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327496-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-11-16 | — | — | US | disclosed |
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264554-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK13, CDK3, CDK12 | CDK7 4/4885CCNT1 45/4885CDK9 16/4885 |
| US-20170327496-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNT1 33/4885CDK9 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.